Last updated: February 23, 2026
What is NDC 00591-3137?
NDC 00591-3137 is the National Drug Code identifier for Zolgensma (onasemnogene abeparvovec-xioi). It is a gene therapy approved by the U.S. Food and Drug Administration (FDA) in May 2019 for the treatment of spinal muscular atrophy (SMA) in pediatric patients under 2 years old. It is manufactured by Novartis.
Current Market Landscape
Market Size and Demand
- Target Population: SMA occurs in approximately 1 in 10,000 live births globally. In the U.S., about 400 newborns annually have SMA, with a significant proportion qualifying for Zolgensma.
- Prevalence: Estimated at 1,400 to 2,000 patients in the U.S., with the potential for future expansion due to broader indications.
- Growth Drivers:
- Increasing diagnosis rates facilitated by newborn screening programs.
- Expanding indications to include older children.
- Adoption of gene therapies for severe genetic disorders.
Competitive Overview
- Other Treatments: Spinraza (nusinersen) by Biogen and Evrysdi (risdiplam) by Roche.
- Market Share:
- Zolgensma captured an estimated 60% of recent SMA gene therapy sales.
- Spinraza retains significant market due to longer market presence and established dosing protocols.
- Pricing Strategy:
- Zolgensma costs approximately $2.1 million per infusion, making it one of the most expensive drugs on a single-dose basis.
Price Projections
Pricing Trends
- Initial Price: The gene therapy launched at ~$2.1 million per dose in 2019.
- Pricing Variance Potential:
- Price adjustments depend on healthcare policy shifts, insurance negotiations, and manufacturing costs.
- Future reductions may occur with increased competition or manufacturing efficiency.
Market Penetration and Revenue Forecasts (2023-2028)
| Year |
Estimated Patients |
Market Penetration |
Revenue (USD billions) |
Price per Dose (USD) |
| 2023 |
1,100 |
65% |
2.31 |
2.1 million |
| 2024 |
1,300 |
70% |
2.73 |
2.1 million |
| 2025 |
1,500 |
75% |
3.15 |
2.1 million |
| 2026 |
1,700 |
80% |
3.58 |
2.1 million |
| 2027 |
1,900 |
85% |
4.00 |
2.1 million |
| 2028 |
2,000 |
90% |
4.20 |
2.1 million |
Notes: These projections assume steady approval expansion, increased diagnosis through newborn screening, and consistent payer access.
Impact of Price Adjustments
- If price reductions or discounts are implemented, revenue forecasts could decline proportionally.
- Alternatively, if expanded indications and higher coverage occur, volume increases could offset price decreases.
Key Market Risks and Opportunities
Risks
- Pricing Pressures: Payers may negotiate discounts or implement value-based agreements, reducing revenue.
- Regulatory Changes: New policies might restrict high-cost therapies or favor alternative approaches.
- Manufacturing Bottlenecks: Production capacity constraints could limit sales growth.
Opportunities
- Broader Indications: Extending use beyond SMA in children into adult populations could expand market size.
- New Markets: Entry into European, Asian, and Latin American markets could significantly increase revenue.
- Improved Manufacturing: Cost reductions through manufacturing efficiencies could enable competitive pricing and higher margins.
Summary of Market Dynamics
- As of 2023, Zolgensma remains a high-price, high-demand therapy for SMA.
- Market growth hinges on diagnosis rates aided by newborn screening programs.
- Revenue projections show steady increases through 2028, assuming insurance coverage and broader approval.
- Price projections remain stable barring policy or competitive pressures but could fluctuate with market dynamics.
Conclusion
The U.S. SMA gene therapy market is characterized by high prices, with Zolgensma maintaining dominance driven by efficacy and regulatory approval. Market expansion is primarily dependent on diagnosis rates, approval of additional indications, and payer coverage. Price stability is probable over the short term unless driven by policy reforms or competition.
Key Takeaways
- NDC 00591-3137 (Zolgensma) is a leading gene therapy for SMA, priced around $2.1 million per dose.
- The global market size for SMA therapies is projected to grow as diagnosis and treatment access improve.
- Revenue forecasts suggest annual sales could reach $4.2 billion by 2028, assuming increased patient adoption.
- Pricing remains high but may experience downward pressure due to policy and market factors.
- Expansion into broader indications and markets presents significant growth opportunities.
FAQs
-
What defines the core patient population for Zolgensma?
Pediatric patients under age 2 diagnosed with SMA, with potential expansion into older children and adults.
-
How do price negotiations influence revenue projections?
Negotiations could lead to discounts or value-based agreements, potentially reducing projected revenues.
-
What are the main competitors?
Spinraza and Evrysdi currently compete with Zolgensma, mainly through long-term dosing regimens.
-
How does newborn screening impact market growth?
It allows early diagnosis, increasing the number of eligible patients for treatment.
-
Are there plans to expand Zolgensma's indications?
Investigations into broader age groups and other neuromuscular conditions are ongoing but not yet approved.
References
[1] Food and Drug Administration. (2019). FDA approves gene therapy for rare neurological disease.
[2] Novartis. (2022). Zolgensma (onasemnogene abeparvovec-xioi) prescribing information.
[3] MarketWatch. (2023). SMA gene therapy market analysis and forecasts.
[4] EvaluatePharma. (2023). Global orphan drug sales and projections.
[5] IQVIA. (2022). U.S. pharmaceutical market data and price trends.
